MAPK7 gene controls proliferation, migration and cell invasion in osteosarcoma
Francine Tesser-Gamba
Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Morphology and Genetics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorLuana Joyce da Silva Lopes
Department of Clinical and Experimental Oncology, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorAntonio Sergio Petrilli
Department of Pediatrics, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorCorresponding Author
Silvia Regina Caminada Toledo
Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Morphology and Genetics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Clinical and Experimental Oncology, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Correspondence to: Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, Rua Botucatu, 743, 8th floor, Vila Clementino São Paulo, São Paulo 04023-062, Brazil.
Search for more papers by this authorFrancine Tesser-Gamba
Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Morphology and Genetics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorLuana Joyce da Silva Lopes
Department of Clinical and Experimental Oncology, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorAntonio Sergio Petrilli
Department of Pediatrics, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Search for more papers by this authorCorresponding Author
Silvia Regina Caminada Toledo
Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Morphology and Genetics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Department of Clinical and Experimental Oncology, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, São Paulo-SP, Brazil
Correspondence to: Department of Pediatrics, Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of São Paulo, Rua Botucatu, 743, 8th floor, Vila Clementino São Paulo, São Paulo 04023-062, Brazil.
Search for more papers by this authorAbstract
Osteosarcomas (OS) are the most common malignant bone tumors, and the identification of useful tumor biomarkers and target proteins is required to predict the clinical outcome of patients and therapeutic response as well as to develop novel therapeutic strategies. In our previous study, MAPK7 has been identified as a candidate oncogene, and a promising prognostic marker for OS. Sequential activation of protein kinases within the mitogen-activated protein kinase (MAPK) cascades is a common mechanism of signal transduction in many cellular processes. In this study, we investigated the behavior of MAPK7 gene in OS cell lines. Technical viability, proliferation, migration, invasion, and apoptosis were used to evaluate the function of the MAPK7 gene. We evaluated the behavior of the OS cells with MAPK7 gene silenced, not silenced, and exposed to the main chemotherapy drugs used in OS treatment. We found that silenced MAPK7 gene is effective at suppressing cell proliferation, inhibiting cell migration, and invasion. Furthermore, MAPK7 is an important activator of transcription factors and is the main expression modulator of other key genes in the MAPK pathway. In summary, our study suggests that MAPK7 might be a promising therapeutic target for OS. © 2015 Wiley Periodicals, Inc.
Supporting Information
Additional supporting information may be found in the online version of this article at the publisher's web-site.
| Filename | Description |
|---|---|
| mc22420-sup-0001-SupInfo-S1.pdf258 KB | Supplementary Material 1 - a) Kruskal-Wallis test. Expression of MAPK7 gene expression in cell lines compared to normal bone; c) Growth curve of cell lines. |
| mc22420-sup-0002-SupInfo-S2.pdf493.7 KB | Supplementary Material 2 - Non-linear regression test - Dose-response-inhibition. IC50 and dose-response calculation of the main chemotherapy drugs used in the treatment of OS (cisplatin, doxorubicin and methotrexate). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Gorlick R, Anderson P, Andrulis I. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 2003; 9: 5442–5453.
- 2 Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 2000; 82: 85–87.
- 3
Huvos AG.
Osteosarcoma in adolescents and young adults: New developments and controversies. Commentary on pathology.
Cancer Treat Res
1991;
62: 375–377.
10.1007/978-1-4615-3518-8_48 Google Scholar
- 4 Wang LL. Biology of osteogenic sarcoma. Pedriatr Cancer 2005; 11: 294–305.
- 5 Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996; 56: 2434–2439.
- 6 Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143–180.
- 7 Pearson G, Robinson F, Beers GT, et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22: 153–183.
- 8 Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50–83.
- 9 Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239–252.
- 10 Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807–869.
- 11 Tesser-Gamba F, Petrilli AS, Alves MTS, Garcia-Filho RJ, Juliano Y, Toledo SRC. MAPK7 and MAP2K4 as Prognostic Markers in Osteosarcoma. Human Pathology 2012; 43: 994–1002.
- 12 Salinas-Souza C, Oliveira ID, Oliveira R, Alves MTS, Petrilli AS, Toledo SRC. Establishment and cytogenetic characterization of a cell line from a pulmonary metastasis of osteosarcoma. Cytotechnology 2013; 65: 347–353.
- 13 Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res. 2005; 65: 7699–7706.
- 14 Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 2006; 18: 753–760.
- 15 Roberts OL, Holmes K, Muller J, Cross DA, Cross MJ. ERK5 and the regulation of endothelial cell function. Biochem Soc Trans 2009; 37: 1254–1259.
- 16 Lee JD, Ulevitch RJ, Han J. Primary structure of BM K1: A new mammalian map kinase. Biochem Biophys Res Commun 1995; 213: 715–724.
- 17 Buschbeck M, Ullrich A. The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 2005; 280: 2659–2667.
- 18 Lennartsson J, Burovic F, Witek B, Jurek A, Heldin CH. Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. Cell Signal 2010; 22: 955–960.
- 19 Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS ONE 2009; 4: 5565.
- 20 Sawhney RS, Liu W, Brattain MG. A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 2009; 219: 152–161.
- 21 Kim AM, Lee H, Park YS, Lee Y, Seo SW. ERK5 Regulates Invasiveness of Osteosarcoma by Inducing MMP-9. J Orthop Res 2012; 30: 1040–1044.
- 22 Ramsay AK, McCracken SRC, Soofi M, et al. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 2011; 104: 664–672.
- 23 Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, et al. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol 2012; 302: 582–593.
- 24 Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997; 16: 7054.
- 25 Clape C, Fritz V, Henriquet C, et al. MiR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 2009; 4: e7542.
- 26 Noguchi S, Mori T, Hoshino Y, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211–220.
- 27 Mulloy R, Salinas S, Philips A, Hipskind RA. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003; 22: 5387–5398.
- 28 Hayashi M, Lee JD. Role of the BMK1/ERK5 signaling pathway: Lessons from knockout mice. J Mol Med 2004; 82: 800–808.
- 29 Schramp M, Ying O, Kim TY, Martin GS. ERK5 promotes Src-induced podosome formation by limiting Rho activation. J Cell Biol 2008; 181: 1195–1210.
- 30 Mehta PB, Jenkins BL, McCarthy L, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003; 22: 1381–1389.
- 31 Barros JC, Marshall CJ. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 2005; 118: 1663–1671.
- 32 Gee JM, Howell A, Gullick WJ, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: Impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 2005; 12: S1.
- 33 Weldon CB, Scandurro AB, Rolfe KW, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002; 132: 293–301.
- 34 Carvajal-Vergara X, Tabera S, Montero JC, et al. Multifunctional role of Erk5 in multiple myeloma. Blood 2005; 105: 4492–4499.
- 35 Tesser-Gamba F, Petrilli AS, Paniago MDG, Alves MTS, Garcia-Filho RJ, Toledo SRC. MAPK7 gene polymorphisms-osteosarcoma tumorigenesis and progression? Tumor Biology 2015 (Submitted).
- 36
Chang L,
Karin M.
Mammalian MAP kinase signalling cascades.
Nature
2001;
6824: 37–40.
10.1038/35065000 Google Scholar
- 37 Whitmarsh AJ, Davis RJ. Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem Sci 1998; 23: 481–485.
- 38 Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395: 713.
- 39 Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 1999; 274: 26563.
- 40 Obara Y, Nakahata N. The signaling pathway leading to extracellular signal regulated kinase 5 (ERK5) activation via G-proteins and ERK5-dependent neurotrophic effects. Mol Pharmacol 2010; 77: 10–16.
- 41 Fukuhara S, Marinissen MJ, Chiariello M, Gutkind JS. Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Galpha q and Galpha 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras and Rho-independent pathway. J Biol Chem 2000; 275: 21730–21736.
- 42 Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 2007; 26: 579–585.
